Repository logo
Communities & Collections
All of CIDRZ Publications
  • English
  • العربية
  • বাংলা
  • Català
  • Čeština
  • Deutsch
  • Ελληνικά
  • Español
  • Suomi
  • Français
  • Gàidhlig
  • हिंदी
  • Magyar
  • Italiano
  • Қазақ
  • Latviešu
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Srpski (lat)
  • Српски
  • Svenska
  • Türkçe
  • Yкраї́нська
  • Tiếng Việt
Log In
New user? Click here to register.Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Dadabhai S"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Results Per Page
  • Sort Options
  • Thumbnail Image
    Item
    Effects of preterm birth, maternal ART and breastfeeding on 24-month infant HIV-free survival in a randomized trial.
    (2024-Jul-15) Dadabhai S; Chou VB; Pinilla M; Chinula L; Owor M; Violari A; Moodley D; Stranix-Chibanda L; Matubu TA; Chareka GT; Theron G; Kinikar AA; Mubiana-Mbewe M; Fairlie L; Bobat R; Mmbaga BT; Flynn PM; Taha TE; McCarthy KS; Browning R; Mofenson LM; Brummel SS; Fowler MG; FHI 360, Durham, NC.; St. Jude Children's Research Hospital, Memphis, TN.; Centre for Infectious Disease Research in Zambia, George CRS, Lusaka, Zambia.; National Institute of Allergy and Infectious Diseases/NIH, Rockville, MD.; B.J. Government Medical College, Department of Paediatrics, Pune, India.; Kamuzu University of Health Sciences-Johns Hopkins Research Project, Blantyre, Malawi.; Elizabeth Glaser Pediatric AIDS Foundation, Washington DC, USA.; University of North Carolina Project Malawi, Tidziwe Centre, Lilongwe, Malawi.; Kilimanjaro Christian Medical Centre, Kilimanjaro Clinical Research Institute and Kilimanjaro Christian Medical University College/Kilimanjaro CRS, Moshi, Tanzania.; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD.; University of Zimbabwe Clinical Trials Research Centre, Belgravia, Harare, Zimbabwe.; Division of Global Women's Health, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Soweto.; Department of Paediatrics and Child Health, University of KwaZulu-Natal, Durban, South Africa.; MU-JHU Research Collaboration; Upper Mulago Hill Road, Kampala, Uganda.; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health.; Wits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg.; Child, Adolescent and Women's Health Department, Faculty of Medicine and Health Sciences, University of Zimbabwe, Avondale.; Department of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.; Centre for the AIDS Programme of Research in South Africa and School of Clinical Medicine, University of KwaZulu Natal, Congella, South Africa.; Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA.; CIDRZ; Centre for Infectious Disease Research in Zambia (CIDRZ)
    BACKGROUND: IMPAACT 1077BF/FF (PROMISE) compared the safety/efficacy of two HIV antiretroviral therapy (ART) regimens to zidovudine (ZDV) alone during pregnancy for HIV prevention. PROMISE found an increased risk of preterm delivery (<37 weeks) with antepartum triple ART (TDF/FTC/LPV+r or ZDV/3TC/LPV+r) compared with ZDV alone. We assessed the impact of preterm birth, breastfeeding, and antepartum ART regimen on 24-month infant survival. METHODS: We compared HIV-free and overall survival at 24 months for liveborn infants by gestational age, time-varying breastfeeding status, and antepartum ART arm at 14 sites in Africa and India. Kaplan-Meier survival probabilities and Cox proportional hazards ratios were estimated. RESULTS: Three thousand four hundred and eighty-two live-born infants [568 (16.3%) preterm and 2914 (83.7%) term] were included. Preterm birth was significantly associated with lower HIV-free survival [0.85; 95% confidence interval (CI) 0.82-0.88] and lower overall survival (0.89; 95% CI 0.86-0.91) versus term birth (0.96; 95% CI 0.95-0.96). Very preterm birth (<34 weeks) was associated with low HIV-free survival (0.65; 95% CI 0.54-0.73) and low overall survival (0.66; 95% CI 0.56-0.74). Risk of HIV infection or death at 24 months was higher with TDF-ART than ZDV-ART (adjusted hazard ratio 2.37; 95% CI 1.21-4.64). Breastfeeding initiated near birth decreased risk of infection or death at 24 months (adjusted hazard ratio 0.05; 95% CI 0.03-0.08) compared with not breastfeeding. CONCLUSION: Preterm birth and antepartum TDF-ART were associated with lower 24-month HIV-free survival compared with term birth and ZDV-ART. Any breastfeeding strongly promoted HIV-free survival, especially if initiated close to birth. Reducing preterm birth and promoting infant feeding with breastmilk among HIV/antiretroviral drug-exposed infants remain global health priorities.
  • Thumbnail Image
    Item
    Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study.
    (2025-Feb) Garrett N; Tapley A; Hudson A; Dadabhai S; Zhang B; Mgodi NM; Andriesen J; Takalani A; Fisher LH; Kee JJ; Magaret CA; Villaran M; Hural J; Andersen-Nissen E; Ferarri G; Miner MD; Le Roux B; Wilkinson E; Lessells R; de Oliveira T; Odhiambo J; Shah P; Polakowski L; Yacovone M; Samandari T; Chirenje Z; Elyanu PJ; Makhema J; Kamuti E; Nuwagaba-Biribonwoha H; Badal-Faesen S; Brumskine W; Coetzer S; Dawson R; Delany-Moretlwe S; Diacon AH; Fry S; Gill KM; Ebrahim Hoosain ZA; Hosseinipour MC; Inambao M; Innes C; Innes S; Kalonji D; Kasaro M; Kassim P; Kayange N; Kilembe W; Laher F; Malahleha M; Maluleke VL; Mboya G; McHarry K; Mitha E; Mngadi K; Mda P; Moloantoa T; Mutuluuza CK; Naicker N; Naicker V; Nana A; Nanvubya A; Nchabeleng M; Otieno W; Potgieter EL; Potloane D; Punt Z; Said J; Singh Y; Tayob MS; Vahed Y; Wabwire DO; McElrath MJ; Kublin JG; Bekker LG; Gilbert PB; Corey L; Gray GE; Huang Y; Kotze P; ICAP at Columbia University, Eswatini Prevention Center, Mbabane, Eswatini.; Nelson Mandela Academic Clinical Research Unit Clinical Research Site, Mthatha, South Africa.; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, USA.; University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, USA.; South African Medical Research Council, Isipingo Clinical Research Site, KwaZulu-Natal, South Africa.; Soweto - Kliptown Clinical Research Site, Soweto, South Africa.; Synergy Biomed Research Institute, East London, South Africa.; Qhakaza Mbokodo Research Clinic, Ladysmith, South Africa.; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA.; COVID-19 Prevention Network, Seattle, USA.; Wits RHI University of the Witwatersrand, Johannesburg, South Africa.; TASK Eden, Western Cape, South Africa.; Synexus Stanza Clinical Research Centre Clinical Research Site, Pretoria, South Africa.; TASK Central, Cape Town, South Africa.; Department of Global Health, University of Washington, Seattle, USA.; KwaZulu-Natal Research Innovation & Sequencing Platform, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.; Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa.; Moi University Clinical Research Centre, Eldoret, Kenya.; Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.; Baylor College of Medicine Children's Foundation-Uganda, Kampala, Uganda.; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, USA.; PHOENIX Pharma (Pty) Ltd, Port Elizabeth, South Africa.; Kisumu Clinical Research Site, Kisumu, Kenya.; South African Medical Research Council, Pretoria, South Africa.; Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, South Africa.; FAMCRU Family Clinical Research Unit, Cape Town, South Africa.; Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.; Joint Clinical Research Centre, Lubowa, Uganda.; MU-JHU Research Collaboration Clinical Research Site, Kampala, Uganda.; Johns Hopkins Research Project, Blantyre, Malawi.; Center for HIV/AIDS Vaccine Immunology, Duke University School of Medicine, Durham, NC, USA.; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA.; Duke University Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.; The Aurum Institute, Rustenburg Clinical Research Site, Rustenburg, South Africa.; Synexus Helderberg, Cape Town, South Africa.; The Aurum Institute, Klerksdorp Clinical Research Site, Klerksdorp, South Africa.; MERC Kempton, Kempton, South Africa.; Malawi Clinical Research Site, Lilongwe, Malawi.; MERC Welkom, Welkom, South Africa.; Cape Town HVTN Immunology Laboratory, Hutchinson Centre Research Institute of South Africa, Cape Town, South Africa.; Hutchinson Centre Research Institute of South Africa, Chris Hani Baragwanath Academic Hospital, Soweto, South Africa.; CFHRZ - Ndola Clinical Research Site, Ndola, Zambia.; Department of Medicine, University of Cape Town, Cape Town, South Africa.; University of Cape Town Lung Institute Clinical Research Site, Cape Town, South Africa.; Josha Research Clinical Research Site, Bloemfontein, South Africa.; MERC Middelburg, Middelburg, South Africa.; Centre for Epidemic Response & Innovation, Stellenbosch, South Africa.; Clinical Trials Research Centre, University of Zimbabwe, Harare, Zimbabwe.; Kombewa Clinical Research Site, Kisumu, Kenya.; Maseno University School of Medicine, Kenya.; UNC Global Projects/Kamwala District Health Centre, Lusaka, Zambia.; UVRI-IAVI HIV Vaccine Program Ltd. Clinical Research Site, Entebbe, Uganda.; Botswana Harvard AIDS Institute, Gaborone, Botswana.; PHRU Matlosana Clinical Research Site, Klerksdorp, South Africa.; MeCRU Clinical Research Site, Pretoria, South Africa.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, USA.; Tembisa Clinic 4, Gauteng, South Africa.; Blantyre Clinical Research Site, Blantyre, Malawi.; CFHRZ Clinical Research Site, Lusaka, Zambia.; Newtown Clinical Research, Johannesburg, South Africa.; Clinical HIV Research Unit/Helen Joseph Clinical Research Site, Johannesburg, South Africa.; Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.; Tongaat Clinical Research Site, KwaZulu-Natal, South Africa.; CIDRZ; Centre for Infectious Disease Research in Zambia (CIDRZ)
    BACKGROUND: With limited access to mRNA COVID-19 vaccines in lower income countries, and people living with HIV (PLWH) largely excluded from clinical trials, Part A of the multicentre CoVPN 3008 (Ubuntu) study aimed to assess the safety of mRNA-1273, the relative effectiveness of hybrid versus vaccine immunity, and SARS-CoV-2 viral persistence among PLWH in East and Southern Africa during the omicron outbreak. METHODS: Previously unvaccinated adults with HIV and/or other comorbidities associated with severe COVID-19 received either one (hybrid immunity) or two (vaccine immunity) 100-mcg doses of ancestral strain mRNA-1273 in the first month, depending on baseline evidence of prior SARS-CoV-2 infection. In a prospective cohort study design, we used covariate-adjusted Cox regression and counterfactual cumulative incidence methods to determine the hazard ratio and relative risk of COVID-19 and severe COVID-19 with hybrid versus vaccine immunity within six months. The ongoing Ubuntu study is registered on ClinicalTrials.gov (NCT05168813) and this work was conducted from December 2021 to March 2023. FINDINGS: Between December 2021 and September 2022, 14,237 participants enrolled, and 14,002 (83% PLWH, 69% SARS-CoV-2 seropositive) were included in the analyses. Vaccinations were safe and well tolerated. Common adverse events were pain or tenderness at the injection site (26.7%), headache (20.4%), and malaise (20.3%). Severe adverse events were rare (0.8% of participants after the first and 1.1% after the second vaccination), and none were life-threatening or fatal. Among PLWH, the median CD4 count was 635 cells/μl and 18.5% had HIV viraemia. The six-month cumulative incidences in the hybrid immunity and vaccine immunity groups were 2.02% (95% confidence interval [CI] 1.61-2.44) and 3.40% (95% CI 2.30-4.49) for COVID-19, and 0.048% (95% CI 0.00-0.10) and 0.32% (95% CI 0.59-0.63) for severe COVID-19. Among all PLWH the hybrid immunity group had a 42% lower hazard rate of COVID-19 (hazard ratio [HR] 0.58; 95% CI 0.44-0.77; p < 0.001) and a 73% lower hazard rate of severe COVID-19 (HR 0.27; 95% CI 0.07-1.04; p = 0.056) than the vaccine immunity group, but this effect was not seen among PLWH with CD4 counts <350 cells/μl or HIV viraemia. Twenty PLWH had persistent SARS-CoV-2 virus at least 50 days. INTERPRETATION: Hybrid immunity was associated with superior protection from COVID-19 compared to vaccine immunity with the ancestral mRNA-1273 vaccine. Persistent infections among immunocompromised PLWH may provide reservoirs for emerging variants. FUNDING: National Institute of Allergy and Infectious Diseases.

CIDRZ copyright © 2025

  • Send Feedback